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Abstract
The new anticonvulsant, lamotrigine, is becoming an important tool in the
treatment of bipolar disorder, including bipolar depression. Its efficacy in
bipolar depression might be linked to its inhibition of serotonin uptake. We
present the case of a female schizoaffective patient successfully treated with
400 mg of lamotrigine developing considerable genital disorder, a side effect
well known from the treatment with selective serotonin reuptake inhibitors
(SSRIs). We suggest that female genital disorder induced by high doses of
lamotrigine is a serotoninergic side effect.
.......................
genitals and erogenous zones was most unpleasant. (This side effectLamotrigine is a novel anticonvulsant known to block
was completely new to the patient, during previous depressions shesodium channels leading to a decrease of presynaptic
was always able to enjoy sexual intercourse.) Until the end of 3/98glutamate release [1] and influencing calcium channels
the dosage remained unchanged with no change of the reported ad-
[2]. Recently, Southam et al. [3] have shown that in pre- verse effect.
parations of rat or human tissue lamotrigine inhibits sero-
tonin uptake. This possible SSRI-like mechanism might
explain lamotrigine’s efficacy in the treatment of bipolar
Discussiondepression [4–6].
Our case suggests that lamotrigine is capable of indu-
cing female genital disorder. In our case this phenomenon
Case Report
seems to be related to the increase of dosage from 200
to 400 mg/day. Within 10 weeks of continued medicationThe 37-year-old patient was admitted to our department in 6/97
with 400 mg/day no reduction of this side effect was ob-with a severe schizomanic episode. Since age 18 she was hospitalised
served. Female genital disorder – as well as abnormalat least 40 times in different psychiatric hospitals because of a schizo-
affective disorder with rapid cycling. Lamotrigine was started in 7/97 ejaculation in men – can be a typical side effect of SSRIs,
and was initially well tolerated. A severe depression developed despite e.g. in a double-blind, placebo-controlled study of paroxe-
200 mg of LamictalÔ monotherapy with a serum concentration of tine in the treatment of panic disorder [7] 13 of 136 women
2.4 mg/l. When in 1/98 lamotrigine was increased to a serum concen- receiving paroxetine (10–40 mg) reported genital disorder
tration of 5.1 mg/ml (400 mg LamictalÔ) the schizomanic episode to
(with 0/47 in the placebo group). We suggest that lamotri-which the patient had meanwhile switched was successfully amelior-
gine’s serotoninergic component that might be desirableated and the patient was dismissed. Unfortunately, at this dosage a
in the treatment of bipolar depression can also lead toconsiderable genital disorder developed, the patient did not only de-
scribe an extinction of her libido, she also described that touching of female genital disorder, a SSRI-typical adverse effect.
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